Literature DB >> 21617115

Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution.

Toshimitsu Yamaoka1, Mark R Frey, Rebecca S Dise, Jessica K Bernard, D Brent Polk.   

Abstract

Upon ligand binding, epidermal growth factor (EGF) receptor (R) autophosphorylates on COOH-terminal tyrosines, generating docking sites for signaling partners that stimulate proliferation, restitution, and chemotaxis. Specificity for individual EGFR tyrosines in cellular responses has been hypothesized but not well documented. Here we tested the requirement for particular tyrosines, and associated downstream pathways, in mouse colon epithelial cell chemotactic migration. We compared these requirements to those for the phenotypically distinct restitution (wound healing) migration. Wild-type, Y992/1173F, Y1045F, Y1068F, and Y1086F EGFR constructs were expressed in EGFR(-/-) cells; EGF-induced chemotaxis or restitution were determined by Boyden chamber or modified scratch wound assay, respectively. Pharmacological inhibitors of p38, phospholipase C (PLC), Src, MEK, JNK/SAPK, phosphatidylinositol 3-kinase (PI 3-kinase), and protein kinase C (PKC) were used to block EGF-stimulated signaling. Pathway activation was determined by immunoblot analysis. Unlike wild-type EGFR, Y992/1173F and Y1086F EGFR did not stimulate colon epithelial cell chemotaxis toward EGF; Y1045F and Y1068F EGFR partially stimulated chemotaxis. Only wild-type EGFR promoted colonocyte restitution. Inhibition of p38, PLC, and Src, or Grb2 knockdown, blocked chemotaxis; JNK, PI 3-kinase, and PKC inhibitors or c-Cbl knockdown blocked restitution but not chemotaxis. All four EGFR mutants stimulated downstream signaling in response to EGF, but Y992/1173F EGFR was partially defective in PLCγ activation whereas both Y1068F and Y1086F EGFR failed to activate Src. We conclude that specific EGFR tyrosines play key roles in determining cellular responses to ligand. Chemotaxis and restitution, which have different migration phenotypes and physiological consequences, have overlapping but not identical EGFR signaling requirements.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617115      PMCID: PMC3154598          DOI: 10.1152/ajpgi.00327.2010

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  46 in total

1.  Epidermal and hepatocyte growth factors stimulate chemotaxis in an intestinal epithelial cell line.

Authors:  D B Polk; W Tong
Journal:  Am J Physiol       Date:  1999-12

Review 2.  Shaping up for shipping out: PLCgamma signaling of morphology changes in EGF-stimulated fibroblast migration.

Authors:  A Wells; M F Ware; F D Allen; D A Lauffenburger
Journal:  Cell Motil Cytoskeleton       Date:  1999-12

3.  ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.

Authors:  Clare Gordon-Thomson; Jackson Jones; Rebecca S Mason; G Philip M Moore
Journal:  Melanoma Res       Date:  2005-02       Impact factor: 3.599

4.  HB-EGF enhances restitution after intestinal ischemia/reperfusion via PI3K/Akt and MEK/ERK1/2 activation.

Authors:  Osama N El-Assal; Gail E Besner
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

5.  p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration.

Authors:  Mark R Frey; Rebecca S Dise; Karen L Edelblum; D Brent Polk
Journal:  EMBO J       Date:  2006-11-30       Impact factor: 11.598

6.  Src is necessary and sufficient for human airway smooth muscle cell proliferation and migration.

Authors:  Vera P Krymskaya; Elena A Goncharova; Alaina J Ammit; Poay N Lim; Dmitry A Goncharov; Andrew Eszterhas; Reynold A Panettieri
Journal:  FASEB J       Date:  2004-12-20       Impact factor: 5.191

7.  Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis.

Authors:  Toshimitsu Yamaoka; Fang Yan; Hanwei Cao; Stuart S Hobbs; Rebecca S Dise; Wei Tong; D Brent Polk
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-13       Impact factor: 11.205

8.  Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.

Authors:  Amy J VanMeter; Adrianna S Rodriguez; Elise D Bowman; Jin Jen; Curtis C Harris; Jianghong Deng; Valerie S Calvert; Alessandra Silvestri; Claudia Fredolini; Vikas Chandhoke; Emanuel F Petricoin; Lance A Liotta; Virginia Espina
Journal:  Mol Cell Proteomics       Date:  2008-08-06       Impact factor: 5.911

9.  Intracellular MUC1 peptides inhibit cancer progression.

Authors:  Benjamin G Bitler; Ina Menzl; Carmen L Huerta; Barbara Sands; Wendy Knowlton; Andrew Chang; Joyce A Schroeder
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

10.  Coordinated integrin and growth factor regulation of primary keratinocyte migration mediated through extracellular signal regulated kinase and phosphoinositide 3-kinase.

Authors:  Alanna Watson; Vincent L Morris; Bosco M C Chan
Journal:  Arch Dermatol Res       Date:  2009-03-28       Impact factor: 3.017

View more
  17 in total

1.  Amniotic fluid inhibits Toll-like receptor 4 signaling in the fetal and neonatal intestinal epithelium.

Authors:  Misty Good; Richard H Siggers; Chhinder P Sodhi; Amin Afrazi; Feras Alkhudari; Charlotte E Egan; Matthew D Neal; Ibrahim Yazji; Hongpeng Jia; Joyce Lin; Maria F Branca; Congrong Ma; Thomas Prindle; Zachary Grant; Sapana Shah; Dennis Slagle; Jose Paredes; John Ozolek; George K Gittes; David J Hackam
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

2.  Polyamines and Gut Mucosal Homeostasis.

Authors:  Jennifer Timmons; Elizabeth T Chang; Jian-Ying Wang; Jaladanki N Rao
Journal:  J Gastrointest Dig Syst       Date:  2012-02-20

Review 3.  Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.

Authors:  S C Nalle; J R Turner
Journal:  Mucosal Immunol       Date:  2015-05-06       Impact factor: 7.313

4.  CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness.

Authors:  G Daniel Grass; Lauren B Tolliver; Momka Bratoeva; Bryan P Toole
Journal:  J Biol Chem       Date:  2013-07-25       Impact factor: 5.157

5.  Loss of MLK3 signaling impedes ulcer healing by modulating MAPK signaling in mouse intestinal mucosa.

Authors:  Pavlo L Kovalenko; Lyudmyla Kunovska; Jian Chen; Kathleen A Gallo; Marc D Basson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-23       Impact factor: 4.052

6.  The ErbB4 ligand neuregulin-4 protects against experimental necrotizing enterocolitis.

Authors:  Steven J McElroy; Shannon L Castle; Jessica K Bernard; Dana Almohazey; Catherine J Hunter; Brandon A Bell; Denise Al Alam; Larry Wang; Henri R Ford; Mark R Frey
Journal:  Am J Pathol       Date:  2014-09-09       Impact factor: 4.307

7.  IBD candidate genes and intestinal barrier regulation.

Authors:  Declan F McCole
Journal:  Inflamm Bowel Dis       Date:  2014-10       Impact factor: 5.325

8.  Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling.

Authors:  Avafia Y Dossa; Oswaldo Escobar; Jamie Golden; Mark R Frey; Henri R Ford; Christopher P Gayer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-11-25       Impact factor: 4.052

9.  Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.

Authors:  X Li; Y Lu; K Liang; J-M Hsu; C Albarracin; G B Mills; M-C Hung; Z Fan
Journal:  Oncogene       Date:  2012-01-09       Impact factor: 9.867

10.  Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes.

Authors:  Ji Zhu; Valerie A Siclari; Fei Liu; Jordan M Spatz; Abhishek Chandra; Paola Divieti Pajevic; Ling Qin
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.